Clinical Trial

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Study acronym: RELIEF
Recruiting
View on ClinicalTrials.gov →
Summary
This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-03-31 -> 2026-09-30 2026-05-12
minor Completion pushed: 2026-03-31 -> 2026-09-30 2026-05-12
Trial Details
NCT Number NCT07408219
Lead Sponsor Novartis Pharmaceuticals
Conditions Chronic Spontaneous Urticaria
Enrollment 350 participants
Start Date 2026-01-17
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-11